Trikafta (elexacaftor/ivacaftor/tezacaftor), new breakthrough therapy for cystic fibrosis
4 Novembre 2019
The U.S. Food and Drug Administration has approved Trikafta (elexacaftor/ivacaftor/tezacaftor), the first triple combination therapy available to treat patients with the most common cystic fibrosis
